



Contact: Yolanda Nesbeth, Ph.D.
Location: 16 Cavendish Court, Lebanon, NH
Email: yn@celdaramedical.com
Tel: 617-320-8521
Website: www.celdaramedical.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Profile

Industry Sector: Life Sciences and Biotechnology

Company Overview: Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. We partner with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery and profitability. With robust funding options, a diverse and high impact Programmatic pipeline, and partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health.

Target Market(s): Major hospitals, clinics and treatment centers nationwide, Scleroderma drug developers and clinicians (Scleroderma diagnostics).

Key Value Drivers

Technology*: MITx is a proprietary monoclonal antibody construct that targets dendritic cells (DC) post-MI. The previously unrecognized role for DC in MI wound healing is noteworthy for at least two reasons. First, immunologists and cardiologists conventionally thought that depletion of DC post-MI would result in catastrophe: i.e. weakened tissues (cardiac rupture) and no new vasculature. Second, the beneficial effect of DC depletion is startling in its magnitude (up to 80% improvement in heart function vs. controls).

Competitive Advantage: Extensive antibody characterization has already been performed by our development partner and a modified version of the antibody is in phase II studies for other indications, indicating low likelihood of toxicity and development risk. Rather than positioning itself as a substitute for existing medications, and surgical procedures, CM is developing a therapy **adjunctive to existing procedures** with the goal of minimizing the incidences of heart injury and failure post reperfusion procedures.

Plan & Strategy: We aim to bring the drug to market in collaboration with our strategic partner but are interested in a cardiovascular focused partner to support the team.

Management

Leadership:

Jake Reder, PhD, Co-Founder, Director, CEO. *Former venture capitalist; corporate NBD/Strategic Alliance Exec, Director of New Ventures at Dartmouth Medical School.*
Michael Fanger, CSO and Chairman. *Founder and former Director of Medarex (sold to BMS for \$2.4B), former Director and CEO of Celldex Therapeutics, Inc.*
Ebo de Muinck, MD, PhD, Co-inventor. *Interventional Cardiologist (Sweden)*
Nicholas Shworak, MD, PhD, Co-developer. *Cardiology Professor (Dartmouth)*
Yolanda Nesbeth, PhD, Program Lead. *Former business consultant, Kauffman Finalist*

Board of Directors:

Eric Achtmann, Director. *Serial entrepreneur, former McKinsey consultant*
Kennett Burnes, Director. *CEO Cabot Corporation, Chairman of the Board of Trustees of the Schepens Eye Research Institute*
Steven Gillis, Director. *Managing Director, ARCH Venture Partners*
Steven Potter, Director. *Founder and CEO, Allyon Solutions.*
Jan van de Winkel, Director. *President, CEO, Co-Founder Genmab*

Product Pipeline

At Market

Scleroderma Diagnostics

In Development

(Please click here for Celdara Medical Pipeline)

Program	Lead Optimization	Preclinical	IND	Clinical Phase	
				Ph I	Ph II
OnCyte Cellular Therapy for Cancer	▶				
Myocardial Infarction Therapeutics (MITx)	▶				
Anti-inflammatory Therapy for sepsis and MI	▶				